bluuebunny/crossref_metadata_2025 huggingface dataset:
Molecular clues into the pathogenesis of statin‐mediated muscle toxicity
Authors: Baker Steven K.
Published: February 2005

The pathophysiology of statin‐mediated muscle dysfunction is poorly defined. Reductions in skeletal muscle membrane cholesterol were initially thought to account for the range of myopathic reactions, e.g., myalgia, elevated serum creatine kinase, or rhabdomyolysis. This assumption however, does not consider a potential role of the isoprenoids in the pathophysiology of statin myopathy. The observation that derangements in mevalonate kinase (MK), but not more distal enzymes of cholesterologenesis, are associated with a skeletal myopathy suggests a critical role for the isoprenoids in the maintenance of muscle. Statins also deplete the isoprenoid pool by inhibiting the enzyme, β‐hydroxy‐β‐methylglutaryl coenzyme A reductase, which is upstream of MK. Identifying candidate proteins that are both dependent on isoprenoid‐mediated modification and associated with muscle disease, when genetically mutated, offers further insight into potential mechanisms of statin myopathy. For example, lamin A/C, selenoprotein N, α‐ and β‐dystroglycan, and cytoskeletal G‐proteins all require isoprenylation for optimal function. Understanding the pleiotropic effects of protein prenylation, and the potential consequences of a generalized insufficiency of this form of protein modification, may help clarify the molecular pathogenesis of statin myopathy. Muscle Nerve, 2005
Specific dissociation behavior of a polycarboxylate having three kinds of hydroxyl groups
Authors: Sunohara Tomoko , Satoh Mitsuru
Published: February 2005

Dissociation behavior of a hydrophilic copolymer having three kinds of hydroxyl groups, ie primary OH on α‐hydroxyallyl alcohol component, hemiacetal OH on cyclic hemiacetal component and tertiary OH on α‐hydroxyacrylate component, was investigated as a function of the polymer constitution to study effects from possible intramolecular hydrogen bonds between the carboxyl group and those hydroxyl groups. The apparent dissociation constant, pKa, decreased with increasing fraction of the hemiacetal component, suggesting that the carboxyl anion is stabilized by intramolecular hydrogen bonding with the hemiacetal OH group. Furthermore, the decrease in pKa value was more significant at the lower degrees of dissociation, α. This dissociation behavior was found to be consistent with IR peak shifts to higher wavenumbers observed for the asymmetric vibration band of COO−, which were more significant with decreasing α and for copolymers with larger hemiacetal contents. Effects from the lactone ring, formed during titration, on the pKa values are also discussed. Copyright © 2005 Society of Chemical Industry
A proteome analysis of conditioned media from human neonatal fibroblasts used in the maintenance of human embryonic stem cells
Authors: Prowse Andrew B. J. , McQuade Leon R. , Bryant Katherine J. , Van Dyk Derek D. , Tuch Bernard E. , Gray Peter P.
Published: February 2005

The pathways involved in the maintenance of human embryonic stem (hES) cells remain largely unknown, although some signaling pathways have been identified in mouse embryonic stem (mES) cells. Fibroblast feeder layers are used to maintain the undifferentiated growth of hES cells and an examination of the conditioned media (CM) of human neonatal fibroblasts (HNFs) could provide insights into the maintenance of hES cells. The neonatal foreskin fibroblast line (HNF02) used in this study was shown to have a normal 2n = 46, XY chromosomal complement and to support the undifferentiated growth of the Embryonic Stem Cell International Pte. Ltd.‐hES3 cell line. The CM of HNF02 was examined using two‐dimensional liquid chromatography‐tandem mass spectrometry (2‐D LCMS) and two‐dimensional electrophoresis (2‐DE) followed by matrix‐assisted laser desorption/ionization‐time of flight tandem mass spectrometry (2‐DE/MALDI). A total of 102 proteins were identified, 19 by 2‐DE/MALDI, 53 by 2‐D LCMS and 30 by both techniques. These proteins were classified into 15 functional groups. Proteins identified in the extracellular matrix and differentiation and growth factor functional categories were considered most likely to be involved in the maintenance of hES cell growth, differentiation and pluripotency as these groups contained proteins involved in a variety of events including cell adhesion, cell proliferation and inhibition of cell proliferation, Wnt signaling and inhibition of bone morphogenetic proteins.
Identification of post‐translational modifications that occur during sperm maturation using difference in two‐dimensional gel electrophoresis
Authors: Baker Mark A. , Witherdin Roxanne , Hetherington Louise , Cunningham‐Smith Kelly , Aitken R. John
Published: February 2005

Difference in two‐dimensional (2‐D) gel electrophoresis (DIGE) is a novel method for analyzing up to three samples in one 2‐D gel and using the information gained to study post‐translational modifications of proteins. We describe the use of DIGE to isolate and characterize those proteins that undergo processing in spermatozoa as they transit the epididymal tract. We find up to 60 protein spots are significantly modified as sperm traverse the epididymis. In this article, we report eight unambiguous protein identifications and demonstrate that one protein, the β‐subunit of the mitochondrial F1‐ATPase, is serine‐phosphorylated as sperm undergo epididymal maturation. We suggest that phosphorylation of this particular protein in a cAMP‐dependent manner may contribute to the mechanisms by which motility is conferred upon spermatozoa.
Effect of thyroxine on abnormal pancreatic proteomes of the hypothyroid rdw rat
Authors: Satoh Mamoru , Haruta‐Satoh Eri , Omori Akira , Oh‐Ishi Masamichi , Kodera Yoshio , Furudate Sen‐Ichi , Maeda Tadakazu
Published: February 2005

A mutation in the thyroglobulin (Tg) gene is the primary cause of hereditary dwarfism and hypothyroidism in the rdw rat. Despite the Tg mutation that causes a Tg shortage, rdw rats survive. The present study examines the influences of this condition on the pancreatic proteome. Normal control (group 1; n = 19) and rdw rats that did not receive L‐thyroxine (T4) (group 2; n = 27) were sacrificed from 4 to 56 weeks after birth. The rdw rats were supplemented either with daily intraperitoneal injections of T4 from 3 to 28 days after birth (group 3; n = 4) or with normal thyroid tissues grafted at 4 weeks of age (group 4; n = 3). Groups 3 and 4 were sacrificed 12 weeks after birth. Pancreatic proteomes analyzed by two‐dimensional gel electrophoresis showed that levels of at least four pancreatic proteins were higher in group 2 than in group 1, and that those of four were lower. Cluster decomposition and principal component analysis of the eight protein contents showed that groups 1 and 2 were separated into two clusters and that pancreatic proteomes of group 4 were better normalized than those of group 3. Injecting T4 into group 3 was temporarily effective, whereas the thyroid graft to group 4 provided a continuous positive effect, which concurred with the increased body weight of the other two groups of rdw rats that received grafts of normal thyroids.
Effect of training datasets on support vector machine prediction of protein‐protein interactions
Authors: Lo Siaw Ling , Cai Cong Zhong , Chen Yu Zong , Chung Maxey C. M.
Published: February 2005

Knowledge of protein‐protein interaction is useful for elucidating protein function via the concept of ‘guilt‐by‐association’. A statistical learning method, Support Vector Machine (SVM), has recently been explored for the prediction of protein‐protein interactions using artificial shuffled sequences as hypothetical noninteracting proteins and it has shown promising results (Bock, J. R., Gough, D. A., Bioinformatics 2001, 17, 455–460). It remains unclear however, how the prediction accuracy is affected if real protein sequences are used to represent noninteracting proteins. In this work, this effect is assessed by comparison of the results derived from the use of real protein sequences with that derived from the use of shuffled sequences. The real protein sequences of hypothetical noninteracting proteins are generated from an exclusion analysis in combination with subcellular localization information of interacting proteins found in the Database of Interacting Proteins. Prediction accuracy using real protein sequences is 76.9% compared to 94.1% using artificial shuffled sequences. The discrepancy likely arises from the expected higher level of difficulty for separating two sets of real protein sequences than that for separating a set of real protein sequences from a set of artificial sequences. The use of real protein sequences for training a SVM classification system is expected to give better prediction results in practical cases. This is tested by using both SVM systems for predicting putative protein partners of a set of thioredoxin related proteins. The prediction results are consistent with observations, suggesting that real sequence is more practically useful in development of SVM classification system for facilitating protein‐protein interaction prediction.
18O‐labeling quantitative proteomics using an ion trap mass spectrometer (vol. 5, Issue 1, pp. 16‐23)
Authors: Sakai Jun , Kojima Shinich , Yanagi Kazunori , Kanaoka Masaharu
Published: February 2005

See original http://dx.doi.org/10.1002/pmic.200300885
High‐Density Ozone Disinfection of Medical‐Care Materials for Dental Surgery
Authors: Ohkawa Hiroshi , Tsuji Masao , Ohtsuki Kayoko , Ohnishi Masatoshi , Akitsu Tetsuya
Published: February 2005

Summary: Disinfection was investigated in high‐density ozone produced by a dielectric barrier discharge under atmospheric pressure. Disinfection was studied on three‐dimensional carriers made of hydrophilic vinyl‐polysiloxane impression material and a granular acrylic resin used for oral surgery. The experimental results indicated disinfection of spore‐forming bacteria: Geobacillus stearothermophilus and Bacillus atrophaeus, and selected species of opportunistic pathogens: Aspergillus niger, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, and Candida albicans.

An example of a carrier disinfected in this study (Exafine® mold).

image

An example of a carrier disinfected in this study (Exafine® mold).
Serum levels of phytanic acid are associated with prostate cancer risk
Authors: Xu Jianfeng , Thornburg Todd , Turner Aubrey R. , Vitolins Mara , Case Doug , Shadle John , Hinson Lisa , Sun Jielin , Liu Wennuan , Chang Baoli , Adams Tamara S. , Zheng S. Lilly , Torti Frank M.
Published: February 2005

BACKGROUND

Recent findings of over‐expression of the AMACR gene in prostate cancer and association between sequence variants in the AMACR gene and prostate cancer risk, along with the well established findings of association between prostate cancer risk and over‐consumption of dairy products and red meat, indirectly suggest that phytanic acid, which primarily comes from dietary intake of dairy and red meat and requires the AMACR enzyme for its metabolism, may be associated with prostate cancer risk. In this small case‐control study, we assessed the association between phytanic acid levels and prostate cancer risk.

METHODS

One hundred and four prostate cancer patients and controls were recruited in North Carolina. Serum levels of phytanic acid were measured using a gas liquid chromatography/mass spectroscopy analysis, and a food frequency questionnaire was administered to each individual to assess dietary intake.

RESULTS

Three key findings are reported. First, there was a high correlation between two independent measurements of phytanic acid levels from the same individuals and the levels of phytanic acid were within the expected range, suggesting that serum levels of phytanic acid levels can be reliably measured in large epidemiological studies. Second, serum levels of phytanic acid among prostate cancer patients were significantly higher than that of unaffected controls, suggesting an association between phytanic acid and prostate cancer risk. Lastly, there was a significantly positive correlation between serum levels of phytanic acid and dietary intake of dairy and red meat servings during the year prior to the serum measurement.

CONCLUSIONS

Although the results from our study suggest phytanic acid levels may be associated with prostate cancer risk, they were based on a study with a small sample size. Much larger studies are required to confirm these important findings. © 2005 Wiley‐Liss, Inc.
Toxic and repellent effects of Baccharis salicifolia essential oil on Tribolium castaneum
Authors: García Matías , Donadel Osvaldo J , Ardanaz Carlos E , Tonn Carlos E , Sosa Marta E
Published: February 2005

Allelochemical effects were observed when Tribolium castaneum (Herbst) adults were treated with Baccharis salicifolia (Ruiz & Pavon) Pers essential oil. The main biological activities were toxicity and repellence. Terpenes present in the essential oil were identified by GC‐MS, and some authentic samples were tested to assess their activity individually. The most acutely toxic compounds after 3 days were β‐pinene and pulegone. Most of the monoterpenes elicited symptoms indicative of neurotoxicity. The most repellent compound was α‐terpineol. Toxic and repellent effects of chemical derivatives of the major sesquiterpene present in B salicifolia essential oil, as well as a series of monoterpenes, were evaluated in order to investigate structure‐activity relationships. The reduced derivatives of the monoterpenes and sesquiterpenes were more repellent that their carbonyl analogues. In addition, unsaturation in the germacrane skeleton enhanced repellent activity. Copyright © 2005 Society of Chemical Industry
Enhanced binding of dopamine D1 receptors in caudate‐putamen subregions in High‐Yawning Sprague‐Dawley rats
Authors: Díaz‐Romero Marilú , Arias‐Montaño José Antonio , Eguibar José R. , Flores Gonzalo
Published: February 2005

Previous reports have shown that the inbred High‐Yawning (HY) and Low‐Yawning (LY) rats differ in several behavioral characteristics related to mesolimbic and nigrostriatal dopamine (DA) function. To determine if differential expression of DA receptors or DA transporter may mediate the behavioral differences in these two sublines of the Sprague‐Dawley rat, we performed a quantitative autoradiography study of the DA D1‐like, D2‐like, and DA‐transporter binding in the basal ganglia and nucleus accumbens. The results show that levels of the D1 binding in the caudate‐putamen of the HY rat were higher than in the LY animals, whereas no significant differences in the DA D2 receptors and DA transporter were noted in these sublines. These data suggest that the differences in DA receptors in D1 binding in HY rats may in part have contributed to the behavioral differences related to DA functions such as grooming and penile erection. Our findings are consistent with previous reports showing a decrease in the behavioral responses after systemic administration of DA agonist in LY compared to HY rats. Synapse 56:69–73, 2005. © 2005 Wiley‐Liss, Inc.
Pollen grains bind to lung alveolar type II cells (A549) via lung surfactant protein A (SP-A)
Authors: Malhotra Rajneesh , Haurum John , Thiel Steffen , Jensenius J. -C. , Sim Robert B.
Published: February 2005

Lung surfactant protein A (SP-A) is the most abundant surfactant-associated protein present in the lung. A receptor for SP-A has been shown to be present on A549 alveolar type II cells and on other cell types, including alveolar macrophage. The SP-A receptor on A549 cells has been identified as the collectin receptor, or C1q receptor, which binds several structurally-related ligands. SP-A contains C-type lectin domains, but the role of carbohydrate binding by SP-A in physiological and pathological phenomena is not yet established. In this paper we report the binding of SP-A to pollen from Populus nigra italica (Lombardy Poplar), Poa pratensis (Kentucky blue grass), Secale cerale (cultivated rye) and Ambrosia elatior (short ragweed). Saturable and concentration dependent binding of SP-A to pollen grains was observed. Interaction of SP-A with pollen grains takes place through waterextractable components, in which the major species present, in Lombardy poplar pollen, are 57 kD and 7 kD (glyco)proteins. The binding of SP-A to pollen grains and their aqueous extracts was calcium ion dependent and was inhibited by mannose, and is therefore mediated by the lectin domain. Binding of SP-A to pollen grains was found to mediate adhesion of pollen grains to A549 cells. The results suggest that pollen grains or other carbohydrate-bearing particles (e. g. microorganisms) could potentially interact with different cell types via the collectin receptor (C1q Receptor) in the presence of SP-A.
Tetracyclines modulate cytosolic Ca2+ responses in the osteoclast associated with “Ca2+ receptor” activation
Authors: Bax Christopher M. R. , Shankar Vijai S. , Towhidul Alam A. S. M. , Bax Bridget E. , Moonga Baljit S. , Huang Christopher L.-H. , Zaidi Mone , Rifkin Barry R.
Published: February 2005

We report the effects of tetracycline analogues on cytosolic Ca2+ transients resulting from application of ionic nickel (Ni2+), a potent surrogate agonist of the osteoclast Ca2+ “receptor”. Preincubation with minocycline (1 mg/l) or a chemically modified tetracycline, 4-dedimethyl-aminotetracycline (CMT-1) (1 or 10 mg/l), resulted in a significant attenuation of the magnitude of the cytosolic [Ca2+] response to an application of 5 mM-[Ni2+]. Preincubation with doxycycline (1 or 10 mg/l) failed to produce similar results. In addition, application of minocycline alone (0.1–100 mg/l) resulted in a 3.5-fold elevation of cytosolic [Ca2+]. The results suggest a novel action of tetracyclines on the osteoclast Ca2+ “receptor”.
The effect of tetracyclines on quantitative measures of osteoclast morphology
Authors: Zaidi Mone , Moonga Baljit S. , Huang Christopher L.-H. , Alam A.S.M. Towhidul , Shankar Vijai S. , Pazianas Michael , Eastwood John B. , Datta Harish K. , Rifkin Barry R.
Published: February 2005

We report the effects of the tetracycline analogues 4-dedimethylaminotetracycline (CMT-1) and minocycline on osteoclast spreading and motility. Both agents influenced the morphometric descriptor of cell spread area, ρ, producting cellular retraction or an R effect (half-times: 30 and 44 minutes for CMT-1 and minocycline, respectively). At the concentrations employed, the tetracycline-induced R effects were significantly slower than, but were qualitatively similar to, those resulting from Ca2+ “receptor” activation through the application of 15 mM-[Ca2+] (slopes: −1.25, −0.18, and −4.40/minute for 10 mg/l-[CMT-1], 10 mg/l-[minocycline] and 15 mM-[Ca2+], respectively). In contrast, the same tetracycline concentrations did not influence osteoclast margin ruffling activity as described by μ, a motility descriptor known to be influenced by elevations of cellular cyclic AMP. Thus, the tetracyclines exert morphometric effects comparable to changes selectively activated by occupancy of the osteoclast Ca2+ “receptor” which may act through an increase in cytosolic [Ca2+].
Retroviruses and Oncogenes I
Authors: Varmus Harold E.
Published: February 2005

The relationship between retroviral genes and oncogenes is described
Gamma-glutamyltransferase induction by dexamethasone in cytochrome P-450-depleted rat liver
Authors: Tongiani Roberto , Paolicchi Aldo , Chieli Elisabetta
Published: February 2005

The effects of the cytochrome P-450 depletion by cobaltic protoporphyrin IX on the postnatal glucocorticoid-inducibility of the membrane-bound enzyme gamma-glutamyltransferase have been assessed in the rat liver. Dexamethasone-induced gamma-glutamyltransferase activity in 14-, 28- and 77-day-old rats was high, weak and absent, respectively, and inversely correlated with the physiological cytochrome P-450 activity. In the liver acinus, the enzyme was reexpressed by the zone 1 and zone 2 hepatocytes in suckling rats, substantially only by the zone 1-hepatocytes in just weaned rats. Following cytochrome P-450 depletion, gamma-glutamyltransferase induction by dexamethasone was more rapid, more intense and more extended in the liver, acinus, occurring also in the zone 3 hepatocytes in suckling rats, in the zone 2 and a few zone 3 hepatocytes in just weaned rats. Further, the enzyme induction occurred also in adult rats in the zone 1 and in some zone 2 cells. This shows that cytochrome P-450 modulates the extent of hepatic gamma-glutamyltransferase induction by dexamethasone in postnatal rat-hepatocytes. The phenomenon may be consequent on hormone biotransformation changes caused by the cytochrome P-450 depletion.
Expression of a human proenkephalin a cDNA in Escherichia coli
Authors: Monstein Hans-Jürg
Published: February 2005

A 1000 base pair cDNA coding for the entire human proenkephalin A(proA) polypeptide was subcloned into the multifunctional pMPV 2911/M E. coli vector. The recombinant plasmid was found to express an approximately 30 kDa prohormone, which was recognized by a Met-Arg6-Phe2 antibody, directed against the C-terminal part of the enkephalin A prohormone. The expression of human proenkephalin A cDNA should thus permit the rapid purification of unfused recombinant enkephalin A prohormone, which itself may provide a model substrat to identify endoproteolytic processing activities.
Cell-surface and secreted proteinases and guanidinobenzoatase activity
Authors: Perry Johanna K. , Kenneth Scott G.
Published: February 2005

Hydrolysis of p-nitrophenyl guanidinobenzoate is characteristic of a tumour cell surface proteinase. We found this activity in three transformed or tumour cell lines, but not in two normal fibroblast strains. Immunochemical inhibition of plasminogen activator activity did not affect guanidinobenzoatase activity.
Autoinfarcted Wandering Spleen and Fatal Pneumococcal Sepsis in an Infant
Authors: Breisch Eric A. , Krous Henry F.
Published: February 2005

A wandering or ectopic spleen, a rare congenital condition caused by improper fixation of the ligamentous attachments, was identified during a postmortem examination of a 10-month-old female who had died of Streptococcus pneumoniae sepsis. The wandering spleen was autoinfarcted and adherent to the left hepatic lobe, with resultant functional hyposplenism.
A meta‐analysis of the effect of angiotensin‐converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction
Authors: Abdulla Jawdat , Abildstrom Steen Z. , Christensen Erik , Kober Lars , Torp‐Pedersen Christian
Published: February 2005

Aim:

To determine by meta‐analysis whether angiotensin‐converting enzyme (ACE) inhibitors improve exercise tolerance in patients with symptomatic left ventricular systolic dysfunction (LVSD).

Methods and results:

After literature search 13 multi‐centre double blind parallel group trials that evaluated the effect of ACE inhibitors vs. placebo on exercise duration were selected. Ninety‐four percent of patients were in New York Heart Association class II–IV. The studies were combined using the Cochrane meta‐analysis program (Review manager version 4.1). Analyses according to treatment period, exercise protocols and publication periods were performed. Treatment with ACE inhibitor over 4–12 weeks resulted in a beneficial effect on exercise duration (P=0.003 and P=0.0008 for 4‐ and 12‐weeks treatment, respectively), but the magnitude of improvements did not exceed 30 s corresponding to only 5% compared with placebo.

Conclusion:

In addition to the pronounced effect on mortality and morbidity in patients with symptomatic LVSD, ACE inhibitors have improving effect on functional capacity measured as exercise tolerance time.
Introduction of intravenous amiodarone has little impact on survival of in‐hospital resuscitation
Authors: Pollak P. , Wee V. , Martin J. , Zarnke K.B.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P3–P3; doi:
Reasons for failing screening
Authors: Mulvaney J.K. , Mant T. , Amin D. , Angell M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P3–P3; doi:
Regulatory considerations for a standard clinical development plan for registration in the us and eu and the nonclinical studies required at each stage
Authors: Curley R. , Bigora S.E.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P4–P4; doi:
Increase in methylprednisolone systemic exposure following coadministration with aprepitant
Authors: Iwamoto M. , McCrea J. , Mazina K.E. , Majumdar A. , Gargano C. , Hesney M. , Goldwater D.R. , Petty K.J. , Deutsch P.J. , Gottesdiener K.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P5–P5; doi:
Evaluation of the effect of aprepitant on CYP3A4 activity using midazolam as a probe
Authors: Majumdar A. , McCrea J. , Busillo J. , Panebianco D. , Dru J. , Constanzer M. , Goldberg M.R. , Murphy G. , Gottesdiener K. , Blum R. , Lates C.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P6–P6; doi:
Efavirenz is a specific phenotyping tool for cytochrome P450 2B6: Implications for HIV therapy
Authors: Desta Z. , Ward B.A. , Hall S.D. , Flockhart D.A.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P7–P7; doi:
Cerebrospinal fluid pharmacokinetics of LY450108 in healthy human subjects
Authors: Jhee S.S. , Chalon S. , Cleton A. , Brandt J.E. , Chappell A.S. , Francisco M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P8–P8; doi:
Monitoring lithium in breast milk: An individualized approach for breastfeeding mothers
Authors: Moretti M.E. , Koren G. , Verjee Z. , Ito S.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P9–P9; doi:
Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease
Authors: Koren G. , Kopecky E.A. , Jacobson S. , Joshi P. , Harsanyi Z.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P9–P9; doi:
Role of CYP3A in the metabolism, disposition and clinical effects of methadone in humans
Authors: Whittington D. , Sheffels P. , Hoffer C.J. , Kharasch E.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P17–P17; doi:
Alfentanil and fexofenadine combination to probe intestinal CYP3A and P‐glycoprotein activities
Authors: Walker A. , Hoffer C.J. , Sheffels P. , Kharasch E.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P17–P17; doi:
The effect of age on triazolam hydroxylation in human liver microsomes from males
Authors: Patki K.C. , von Moltke L.L. , Harmatz J.S. , Greenblatt D.J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P18–P18; doi:
Ritonavir impairs clearance and enhances toxicity of trazodone
Authors: Greenblatt D.J. , von Moltke L.L. , Harmatz J.S. , Fogelman S. , Chen G. , Shader R.I.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P18–P18; doi:
Organic cation transport in the human mammary gland
Authors: Ito Shinya , Kwok Bruce , Gao Wen , Xu Haibo , Dhillon Upinder , Lee Ronita , Semple John , Nezu Jun‐ichi , Harper Patricia
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P19–P19; doi:
Novel interactions in the oral absorption of hydrophilic cations (HCS): A clinical study with ranitidine and famotidine
Authors: Brandquist C.M. , Ng C. , Thakker D.R. , Brouwer K.L.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P19–P19; doi:
CYP3A activity as determined by midazolam PK, is similar between Chinese, Indians and Caucasians before and after rifampicin treatment but not as determined by 6B‐OH cortisol formation
Authors: Soon D.K. , Yeo K. , Lim M. , Chan C. , Wise S.D.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P20–P20; doi:
Enantioselective inhibition of human liver cytochrome P450 2C19 by lansoprazole and omeprazole
Authors: Kim M. , Kim K. , Sohn D. , Lee S. , Cha I. , Shin J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P21–P21; doi:
Effect of CYP2D6 genetic polymorphisms on pharmacokinetics of tropisetron
Authors: Oh D. , Kim M. , Cho J. , Lim H. , Hong K. , Chung J. , Bae K. , Yi S. , Shin S. , Jang I.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P21–P21; doi:
The PK and PD properties of ximelagatran in young and elderly, healthy Japanese males
Authors: Johansson L.C. , Nyström P. , Johnsson G. , Nakanishi T. , Eriksson U.G.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P22–P22; doi:
No influence of ethnic origin on the PK and PD properties of ximelagatran in young, healthy males
Authors: Johansson L.C. , Frison L. , Nakanishi T. , Fager G. , Eriksson U.G.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P22–P22; doi:
Pharmacokinetics of recombinant factor VIIa in adults with haemophilia a — a modeling and simulation approach
Authors: Erichsen L. , Klitgaard T.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P22–P22; doi:
Markedly different predictions about insulin pharmacodynamic (PD) measurement feasibility in healthy subjects from recently proposed intravenous glucose tolerance test (IVGTT)‐based insulin‐glucose models
Authors: Groth A.V. , Thomsen M.S.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P23–P23; doi:
Comparison of censored regression (CR) vs standard regression (SR) analyses for modeling relationships between minimum inhibitory concentrations (MIC) and patient‐ and institution‐specific variables
Authors: Hammel J.P. , Bhavnani S.M. , Ambrose P.G. , Forrest A. , Jones R.N. , Piedmonte M.R.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P24–P24; doi:
Novel mathematical models for bacterial growth, death & pharmacodynamics
Authors: Booker B.M. , Forrest A. , Smith P.F.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P24–P24; doi:
Understanding schedule dependence of an irreversible aromatase inhibitor via simulations
Authors: Duan J.Z. , Gobburu J.V.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P24–P24; doi:
The effect of Hemodialysis on the Export of Homocysteine by Erythrocytes
Authors: Urquhart B.L. , House A.A. , Freeman D.J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P26–P26; doi:
Thiopurine S‐Methyltransferase (TPMT) Pharmacogenetics: Role of Chaperone Proteins in variant Allozyme Degradation
Authors: Wang L. , Sullivan W. , Toft D. , Weinshilboum R.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P29–P29; doi:
Ontogeny of Phase II Enzymes: UGT and Sult
Authors: Behm M.O. , Abdel‐Rahman S.M. , Leeder J.S. , Kearns G.L.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P29–P29; doi:
A Comparison of the Pharmacokinetics and Tolerability of Almotriptan in Healthy Adolescents and Adults
Authors: Baldwin J.R. , Fleishaker J.C. , Carel B.J. , Azie N.E.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P30–P30; doi:
Reproducibility of QT Interval Measurements From Holter Recordings
Authors: Callahan T. , Friday K. , Gomez H.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P31–P31; doi:
Influence of Azimilide on CYP2C19 Mediated Metabolism
Authors: Mouelhi M. El , Thompson G.A. , Worley D.J. , Kuzmak B. , Destefano A.J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P32–P32; doi:
An Informal Survey of Pharmacogenetics/Pharmacogenomics (PGTX) in A Sample of IND's and NDA's
Authors: Chou W. , Huang S. , Sahajwalla C.G. , Lesko L.J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P33–P33; doi:
Absence of TH1 or TH2 Cytokine Differentiation After Measles Vaccine Virus Immunization Failure
Authors: Guerrero R. Bonilla , Dhiman N. , O'Kane D.J. , Jacobson R.M. , Poland G.A.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P35–P35; doi:
The Cardiovascular Effects of D‐ and L‐Methamphetamine
Authors: Mendelson J.E. , Foster E. , Ryan E. , Uemura N. , Nath R.P. , Jones R.T.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P36–P36; doi:
Suboxone: A Comparison of Dosing Regimens and in Vivo Dissolution Times With Two Different Sublingual Tablet Formulations
Authors: Nath R.P. , Sequeira G.M. , Rogerson S.L. , Fernandez E. , Jones R.T. , Mendelson J.E.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P36–P36; doi:
A single‐Dose, 2‐Way Crossover, Bioequivalence Study of Dexmethylphenidate With and Without Food in Healthy Subjects
Authors: Teo S. , Scheffler M. , Stirling D. , Thomas S. , Khetani V.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P36–P36; doi:
Pharmacokinetics of IV Pantoprazole in Pediatric Patients
Authors: Ferron G.M. , Schexnayder S. , Marshall J.D. , Blumer J. , Rodarte A. , Abell M.W. , Mako B. , Fraga P. , Getsy J. , Paul J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P37–P37; doi:
Pharmacokinetics of Vancomycin in Children Receiving Peritoneal Dialysis
Authors: Blowey D.L. , Warady B.A. , Manley H.J. , Frye R.F. , Smith C.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P38–P38; doi:
Pantoprazole Disposition in Pediatrics
Authors: Kearns G.L. , Ferron G.M. , James L.P. , Blumer J.L. , Gaedigk A. , Mayer P. , Abel M. , Getsy J.A. , Leeder J.S. , Paul J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P38–P38; doi:
Urinary Excretion of Midazolam, 1‐OH‐Midazolam and 1‐OH‐Midazolam‐Glucuronide in Preterm Neonates
Authors: de Wildt S.N. , Kearns G.L. , Murry D.J. , van den Anker J.N.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P39–P39; doi:
Identifying the Barriers to Conducting Pharmacokinetic and Pharmacodynamic Studies in Pregnant Women
Authors: Uhl K. , Miller M. , Chapman K.K. , Kennedy D.L.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P39–P39; doi:
Identification of Polymorphisms in Human CYP2C8 Gene by Two‐Dimensional Gel Scanning in Healthy Koreans
Authors: Cho J. , Suh Y. , Lee J. , Yi S. , Hong K. , Lim H. , Chung J. , Bae K. , Jang I. , Shin S.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P41–P41; doi:
Pharmacogenetic Testing Using Plasma, Serum or Urine
Authors: Werf M.v. , van der Heiden I.P. , van Fessem M. , van Vliet M. , Lindemans J. , van den Anker J. , van Schaik R. , van Schaik R.H.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P42–P42; doi:
Transient Downregulation of MDR1A Gene Expression in Brains of Endotoxin‐Treated Rats
Authors: Wang J. , Piquette‐Miller M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P42–P42; doi:
Reliability of A Single Omeprazole/Hydroxyomeprazole Plasma Concentration Ratio For CYP2C19 Phenotype Determination in Chinese Subjects
Authors: Yin O.Q. , Tomlinson B. , Waye M.M. , Chow A.H. , Chow M.S.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P43–P43; doi:
Stiripentol (STP) in Childhood Partial Epilepsy: A Randomized Placebo‐Controlled Trial With An Enrichment and Withdrawal Design
Authors: Rey E. , Chiron C. , Tonnelier S. , Brunet M. , Tran A. , D'athis P. , Vincent J. , Dulac O. , Pons G.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P43–P43; doi:
Effect of St. John's Wort on The Pharmacokinetics and Pharmacodynamics of Quazepam
Authors: Kawaguchi A. , Ohmori M. , Tsuruoka S. , Harada K. , Fujimura A.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P44–P44; doi:
In Vitro Screening of Drug Metabolism and Interaction Using HEPG2 Overexpressing Human Drug Metabolizing Enzyme, CYP3A4
Authors: Araki N. , Tsuruoka S. , Sugimoto K. , Ohmori M. , Cui Y. , Maezono S. , Yamazoe Y. , Omasa T. , Fujimura A.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P44–P44; doi:
The Pharmacokinetics, Metabolism and Exretion of Sitafloxacin Following A Single Oral Dose to Healthy Male Subjects
Authors: Yamaguchi M. , Haque N. , Cornelissen K.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P44–P44; doi:
The Single‐Dose Pharmacokinetics of Clopidogrel in Healthy Adult Volunteers
Authors: Grenier J. , Ciric S. , Curry J. , Morelli G. , Arseneault A. , Tanguay M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P47–P47; doi:
Domperidone As A Substrate Marker Drug for CYP3A4 and CYP3A5
Authors: Michaud V. , Simard C. , Morin N. , Turgeon J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P47–P47; doi:
The single‐Dose Pharmacokinetics of Pergolide in Healthy Adult Volunteers
Authors: Grenier J. , Marricco N. Cardillo , Morelli G. , Letarte L. , Farmen R. , Tanguay M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P47–P47; doi:
Population Pharmacokinetics of Omeprazole in Healthy Adults and in Children With Gastroesophageal Reflux Disease
Authors: Marier J. , Dubuc M. , Drouin E. , Fernando A. , Ducharme M. P. , Brazier J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P48–P48; doi:
Pharmacokinetics of Capecitabine Given in Combination With Oxaliplatin: A Pilot Study of Adult Cancer Patients
Authors: Guo X. , Ernst A. , Grem J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P49–P49; doi:
Gastro‐Intestinal Regional Absorption Study of PNU‐96391A in Healthy Volunteers
Authors: Azie N. E. , Adams G. A. , Rodriguez C. A. , Hopkins N. K. , Wilding I.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P50–P50; doi:
Pharmacokinetic Interaction of Gabapentin and Naproxen in Rats and Humans
Authors: Feng M. R. , Ouellet D. , Li W. , Berna K. , Ferreira S. , Knowlton P. , Fountain S. , Randinitis E. , Haig G. , Wesche D.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P50–P50; doi:
First‐Order Versus Michaelis‐Menten Pharmacokinetic Model Selection Using A Mixture Model
Authors: Riley S. P. , Ludden T. M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P51–P51; doi:
Use of The Monte‐Carlo Parametric Expectation Maximization (MC‐PEM) Estimation Method With Important Sampling For Very Sparse Data Settings
Authors: Guzy S. , Bauer B.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P51–P51; doi:
Scaling in hospital prescription orders
Authors: Frattarelli D.A. , Aranda J.V.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P52–P52; doi:
A cox‐inhibiting nitric oxide donator (CINOD): gastric tolerability profile in the rat
Authors: Sharma R.K. , Ojteg G. , Manninen A. , Hallgren A. , Hoogstraate J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P53–P53; doi:
Population pharmacokinetics of intravenous valproic acid in korean patients
Authors: Yim D. , Park H.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P55–P55; doi:
Prediction of CYP3A inhibition using physiologically‐based pharmacokinetic modeling and trial simulation
Authors: Chien J.Y. , Wrighton S.A. , Hall S.D.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P56–P56; doi:
Altered P‐Glycoprotein immunoreactivity but normal function in human peripheral blood mononuclear cells (PBMCS)
Authors: Chinn L.W. , Kroetz D.L.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P58–P58; doi:
Genetic variation and haplotype structure of human multidrug resistance‐associated protein 2(MRP2)
Authors: Nguyen T.D. , Huang C.C. , Kawamoto M. , Carlson E.J. , Herskowitz I. , Giacomini K.M. , Kroetz D.L.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P59–P59; doi:
Functional characterization of genetic variants of the nucleoside transporter, CNT1
Authors: Gray J.H. , Owen R.P. , Urban T.J. , Giacomini K.M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P59–P59; doi:
Interleukin (IL)‐6 downregulates expression of the pregnane X receptor (PXR) in mice
Authors: Hartmann G. , Jekerle V. , Piquette‐Miller M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P60–P60; doi:
Role of CYP3A in the metabolism, disposition and clinical effects of 1‐a‐acetylmethadol (LAAM) in humans
Authors: Whittington D. , Sheffels P. , Hoffer C. J. , Kharasch E. D.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P62–P62; doi:
Effects of argatroban alone or in combination with phen‐procoumon or acenocoumarol on PT, APTT and ecarin clotting time
Authors: Klinkhardt U. , Graff J. , Breddin H. , Harder S.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P62–P62; doi:
Different effects of propranolol, bisoprolol, carvedilol and doxazosin
Authors: Koshucharova G. , Stoschitzky K. , Zweiker R. , Lercher P. , Maier R. , Watzinger N. , Klein W.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P63–P63; doi:
The differential effects of orbofiban and abciximab on platelet release of nitric oxide and superoxide
Authors: Chakrabarti S. , Cox D. , Varghese S. , Sarkar S. , Mascelli M. , Freedman J. E.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P63–P63; doi:
Application of real‐time data assembly (RTDA) to a pivotal phase III pediatric trial: A proactive approach to population pharmacokinetic/pharmacodynamic (PK/PD) dataset creation
Authors: Rubino C. M. , McPhee M. , Vo M. , Jungbluth G. L.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P65–P65; doi:
Pharmacokinetics of sibutramine in healthy subjects under fasting fed conditions
Authors: Abolfathi Z. , Vallée François , Masson É.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P65–P65; doi:
A population analysis of data obtained in phase I‐III clinical trials of HBOC‐201
Authors: Knebel W. , Pearce L. B. , Gawryl M. S. , Pentikis H. S.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P67–P67; doi:
A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastases
Authors: Booth B. P. , Rahman A. , Ibrahim A. , Scher N. , Williams G. , Schran H. , Ma P. , Hsu C. , Gobburu J. V.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P67–P67; doi:
Dose‐response relationship characterization in current anti‐hypertensive drug development
Authors: Gobburu J. V. , Lipicky R. J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P68–P68; doi:
Hypertension and diabetes screening and awareness study (hydra): Prevalence, comorbidity and pharmacological treatment patterns of hypertension and diabetes in primary care in Germany
Authors: Pittrow D. , Kirch W. , Wittchen H. , Unger T. , Krause P. , Sharma A. M. , Ritz E. , Goeke B. , Lehnert H. , Tschoepe D.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P69–P69; doi:
High concentrations of nelfinavir as an independent risk factor for lipodystrophy in HIV‐infected patients
Authors: Treluyer J. , Morini J. , Dimet J. , Gorin I. , Rey E. , Pons G. , Dupin N.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P70–P70; doi:
Saquinavir (SQV) plasma exposure is not influenced by lopinavir (LPV)/ritonavir (RTV) co‐administration compared to a SQV/RTV‐boostered therapy in adults with HIV‐1‐infection
Authors: Nils V. , Staszewski S. , Kurowski M. , Stefan C. , Harder S.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P70–P70; doi:
Evaluation of gender and smoking status differences on neuroendocrine, cognitive and subjective effects after intranasal nicotine (NNS) administration
Authors: Leu J. H. , Rosecrans J. A. , Clore J. N. , Venitz J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P70–P70; doi:
Pharmacokinetics of citalopram after IV infusion
Authors: Bies R. R. , Lotrich F. E. , Smith G. , Muldoon M. , Pollock B. G.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P71–P71; doi:
Evaluation of the maturation of human CYP on the oxidative metabolism of amprenavir
Authors: Treluyer J. , Bowers G. , Cazali N. , Sonnier M. , Rey E. , Pons G. , Cresteil T.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P71–P71; doi:
Population pharmacokinetics (PK) and pharmacodynamics (PD) of quinapril (Q) in infants, children, and adolescents
Authors: Ouellet D. , Olson S. , Roman D. , Keller L. H.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P72–P72; doi:
PPAR gamma activation rapidly increases ACRP30 in non‐diabetic subjects
Authors: Wagner J. A. , Flynn M. E. , Knops A. , Hartford A. H. , Dallob A. L. , Tanaka W. K. , DeSmet M. , Van Dyck K. , Stevens C. , Scherer P. E. , Gottesdiener K. M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P75–P75; doi:
Impact of the CYP2C9 and CYP2D6 polymorphisms for pharmacokinetics of 3R,5S‐ and 3S,5R fluvastatin
Authors: Kirchheiner J. , Kudlicz D. , Meisel C. , Roots I. , Brockmöller J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P75–P75; doi:
Influence of CYP2C9 amino acid polymorphisms on enantioselective metabolism of R‐,S‐phenprocoumon
Authors: Roots I. , Kirchheiner J. , Walter E. , Kammerer B. , Schwab M. , Meisel C. , Brockmöller J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P76–P76; doi:
Pharmacogenetic‐pharmacokinetic relationships for desipramine
Authors: Katz D. A. , Furman K. D. , Grimm D. R. , Bertz R. J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P76–P76; doi:
The heat‐stable enterotoxin receptor, guanylyl cyclase C (GC‐C), is a molecular marker for upper and lower gastrointestinal malignancies
Authors: Schulz S. , Nielsen K. , Birbe R. , Walters R. , Palazzo J. , Waldman S. A.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P76–P76; doi:
Mechanism‐based inhibition of CYP2D6 by paroxetine
Authors: Bertelsen K. M. , Venkatakrishnan K. , von Moltke L.L. , Obach R. Scott , Greenblatt D.J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P77–P77; doi:
Pharmacogenomic studies using paraffin embedded tumor samples
Authors: Rae J. M. , Scheys J. , Cordero K. E. , Johnson M. D.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P77–P77; doi:
Pharmacokinetics (PK) of Garenoxacin in Healthy Subjects and in Subjects With Hepatic Impairment
Authors: Noveck R. J. , Vargas R. , Russo R. , Bello A. , Gajjar D. , Grasela D.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P79–P79; doi:
Effect of Soya Isoflavones on CYP450 Activity in Human Liver Microsomes
Authors: Poston S. E. , Rege B. , Sarkar M. A.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P79–P79; doi:
Population Pharmacokinetic Model of Chlorzoxazone and 6‐Hydroxychlorzoxazone in Renal Failure: Impact of Patient Covariates on CYP2E1 Activity
Authors: Nolin T. D. , Gastonguay M. R. , Bies R. R. , Matzke G. R. , Bernardo J. F. , Aslam N. , Frye R. F.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P80–P80; doi:
Concomitant Use of Gepirone‐er and Lithium: An Interaction Study
Authors: Spaans E. , Timmer C.J. , Machielsen C.S.M. , Grzegorzewski M.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P81–P81; doi:
Increasing Oxybutynin Plasma Levels Results in Improved Treatment Response in Overactive Bladder
Authors: New K. , Sanders S. W.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P83–P83; doi:
Pharmacokinetics and Tolerability of Bosentan in Patients With Mild Liver Impairment
Authors: van Giersbergen P. , Popescu G. , Dingamanse J.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P84–P84; doi:
Reduction In Olanzapine Therapeutic Dosage Using A Subclinical Dose of Fluvoxamine in Patients With Schizophrenia
Authors: Albers L. J. , Reist C. , Ozdemir V. , Marder S. , Raggi M. A.
Published: February 2005

Clinical Pharmacology & Therapeutics (2003) 73, P84–P84; doi: